262 related articles for article (PubMed ID: 34338191)
1. Comparative efficacy and safety of rituximab, mycophenolate, and cyclophosphamide in active antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Int J Clin Pharmacol Ther; 2021 Oct; 59(10):645-653. PubMed ID: 34338191
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of rituximab, mycophenolate, methotrexate, and cyclophosphamide versus azathioprine as maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Int J Clin Pharmacol Ther; 2022 Feb; 60(2):97-105. PubMed ID: 34622770
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of mycophenolate mofetil versus cyclophosphamide in patients with active antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of randomized trials.
Song GG; Lee YH
Z Rheumatol; 2021 Jun; 80(5):425-431. PubMed ID: 32337635
[TBL] [Abstract][Full Text] [Related]
4. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Lupus; 2015 Dec; 24(14):1520-8. PubMed ID: 26162684
[TBL] [Abstract][Full Text] [Related]
5. Comparison of treatment response and serious infection using tacrolimus, tacrolimus with mycophenolate mofetil, in comparison to cyclophosphamide as induction treatment for lupus nephritis.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2020 Oct; 58(10):550-556. PubMed ID: 32691727
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis-a meta-analysis.
Kuzuya K; Morita T; Kumanogoh A
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371435
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of tacrolimus, mycophenolate mofetil, azathioprine, and cyclophosphamide as maintenance therapy for lupus nephritis : A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Z Rheumatol; 2017 Dec; 76(10):904-912. PubMed ID: 27638015
[TBL] [Abstract][Full Text] [Related]
8. A network meta-analysis of randomized controlled trials comparing the effectiveness and safety of voclosporin or tacrolimus plus mycophenolate mofetil as induction treatment for lupus nephritis.
Lee YH; Song GG
Z Rheumatol; 2023 Sep; 82(7):580-586. PubMed ID: 34545430
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of low-dose and high-dose cyclophosphamide as induction therapy for lupus nephritis: a network meta-analysis.
Bae SC; Lee YH
Z Rheumatol; 2019 Jun; 78(5):467-473. PubMed ID: 30039177
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: A Systematic Review and Network Meta-Analysis.
Li K; Yu Y; Gao Y; Zhao F; Liang Z; Gao J
Front Immunol; 2022; 13():859380. PubMed ID: 35444666
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy and Safety of Tacrolimus, Cyclosporin A, Mycophenolate Mofetil, Cyclophosphamide, and Corticosteroids as Induction Therapy for Membranous Lupus Nephritis: A Network Meta-Analysis.
Lee YH; Song GG
Pharmacology; 2022; 107(9-10):439-445. PubMed ID: 35609529
[TBL] [Abstract][Full Text] [Related]
12. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
Aqeel F; Xu L; Salas A; Wen Y; Eid SM; Geetha D
Clin Rheumatol; 2023 Sep; 42(9):2427-2435. PubMed ID: 37225927
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
16. Rituximab Versus Cyclophosphamide for Central Nervous System Involvement of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case Series.
Krishna R; De Giacomi F; Kumar N; Kalina P; Specks U; Baqir M
J Clin Rheumatol; 2021 Mar; 27(2):64-72. PubMed ID: 31567753
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
Tuin J; Stassen PM; Bogdan DI; Broekroelofs J; van Paassen P; Cohen Tervaert JW; Sanders JS; Stegeman CA
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1021-1028. PubMed ID: 31253599
[TBL] [Abstract][Full Text] [Related]
18. ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial.
Dirikgil E; van Leeuwen JR; Bredewold OW; Ray A; Jonker JT; Soonawala D; Remmelts HHF; van Dam B; Bos WJ; van Kooten C; Rotmans J; Rabelink T; Teng YKO
BMJ Open; 2022 Sep; 12(9):e061339. PubMed ID: 36130755
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.
Jones RB; Hiemstra TF; Ballarin J; Blockmans DE; Brogan P; Bruchfeld A; Cid MC; Dahlsveen K; de Zoysa J; Espigol-Frigolé G; Lanyon P; Peh CA; Tesar V; Vaglio A; Walsh M; Walsh D; Walters G; Harper L; Jayne D;
Ann Rheum Dis; 2019 Mar; 78(3):399-405. PubMed ID: 30612116
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis.
Jiang N; Jin S; Yu C; Zhao J; Wang Q; Tian X; Li M; Zeng X
Front Immunol; 2023; 14():1232244. PubMed ID: 37901212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
